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PACs
1 and BACs 2 are used increasingly for long-range physical mapping, 3, 4 positional cloning of disease genes, 5 whole genome sequencing projects 6 and functional studies. 7, 8 However, the lack of convenient techniques for performing genetic manipulations on BACs/PACs in the host E. coli DH10B strain imposes serious limitations for functional analysis.
Homologous recombination in an F plasmid-based vector in E. coli was first used in 1989 to join overlapping Drosophila cosmid fragments to form a 125 kb fragment. 9 Homologous recombination has also been used recently to introduce targeted modifications in BACs, [10] [11] [12] but the available techniques either require the construction of shuttle plasmids or are not directly applicable in DH10B cells.
The bacteriophage Red-Gam and the RecE systems promote homologous recombination between linear DNA fragments and circular plasmid molecules or the host chromosome. 13, 14 The reaction catalysed by the RecE pathway, termed ET cloning, 14 could be transferred to other recBC strains by cloning part of the recET operon into the l-arabinose-inducible expression plasmid pBAD24 to give plasmid pBAD24-trecET (YZ and AFS, 14 with the gam gene of bacteriophage being used as a natural inhibitor of recBCD nuclease, to allow ET cloning in recBC+ strains of E. coli. This plasmid enabled targeted modification of a 76 kb Drosophila P1 clone in its recBC+ host strain (NS3145) with PCR fragments having about 50 bp of homology in each arm.
A second generation BAC/PAC cloning vector, pEBAC140, (Figure 1a , PAI and J-M Vos), combining features of the first generation PAC 1 and BAC 2 cloning systems and the HAEC system 15 was used in the initial efforts to optimize homologous recombination. EBAC/148␤ (Figure 1b) contains the entire ␤-globin locus (about 73 kb) in a 185 kb NotI genomic fragment from clone PAC/148␤, 16 cloned into the NotI site of pEBAC140. A stable human nonerythroid DR cell line was established with EBAC/148␤ under hygromycin selection, carrying EBAC/148␤ in episomal format. 17 Analysis of the untransfected and transfected DR cells containing EBAC/148␤ by RT-PCR, showed that expression of ␤-globin mRNA was only detectable in the transfected cells (data not shown), indicating that EBAC/148␤ contains all the endogenous elements required for expression of the genes at the ␤-globin locus. We wished to introduce modifications to this genomic clone to facilitate functional analysis and gene therapy approaches to thalassaemia.
We obtained precise homologous recombination of PCR fragments of a kanamycin resistance (Km r ) gene (PCRkan50) carrying 50 bp flanking homology arms (Figure 2 ) into the backbone of the chloramphenicolresistant (Cm r ) pEBAC140 vector in the recBC sbcA strains JC8679 and JC9604, 14 to generate pEBAC140::kan50 (data not shown). However, we were unable to transfer the 200 kb EBAC/148␤ clone from DH10B into JC9604 electrocompetent cells for subsequent modification due to host restriction differences between the two strains, nor to introduce the recE pathway into DH10B cells with the pBAD24-trecET plasmid.
Since the recBCD nuclease (exonuclease V) is active in DH10B cells and plays a major role in the degradation of linear double-stranded DNA that is introduced into wildtype cells, 13 it could also play an important role in limiting the efficiency of the recE pathway in DH10B(pBAD24-trecET, pEBAC140) cells. We were thus interested in using the bacteriophage gam gene as an in vivo inhibitor of the recBCD nuclease. A PCR fragment carrying the gam gene was inserted into the pBAD24-trecET plasmid, to produce plasmid pGETrec ( Figure 3 ). With the placement of the gam gene under the same larabinose-inducible promoter as the recE and recT genes, we aimed to control the induction of the recE pathway and inhibition of the recBCD nuclease activity on incoming linear dsDNA in a coordinated manner. pGETrec differs significantly from pBAD-ET␥ 14 in that only the recE gene is inducible by l-arabinose in the latter.
Electroporation of PCRkan140 into DH10B(pGETrec, pEBAC140) cells gave almost 300 recombinants each from two independent electroporations (Table 1 , experiments 1 and 2). Restriction enzyme digestion of 12 independent clones with XhoI or HindIII, enzymes which cut only once in the multicloning site of the pEBAC140 vector and once on PCRkan140, demonstrated that every Cm r Km r recombinant had undergone homologous recombination of Km r recombinants obtained per electroporation is indicated. Electroporation efficiency of each batch of competent cells was measured by an independent electroporation with 10 ng of pZeoSV2 (Invitrogen, Carlsbad, CA, USA) and plating serial dilutions on to low-salt LB (pH 7.5) plates containing 25 g/ml Zeocin (about 1 × 10 8 c.f.u./g). Total number of surviving cells after electroporation was measured by plating serial dilutions of the DH10B(pGETrec, pEBAC140) or DH10B(pGETrec, EBAC/148␤) electroporated competent cells (without addition of DNA) on to LB plates containing 100 g/ml ampicillin and 12.5 g/ml chloramphenicol. Percentage of recombination was measured as percentage of kanamycin-and chloramphenicolresistant colonies per survivors after electroporation. 
Figure 6 Fusion of a luciferase/kanamycin cassette into exon II of the ␤-globin gene by homologous recombination. A luciferase/kanamycin cassette was constructed by cloning the kanamycin resistance gene from pCYPAC2 into the BamHI site of pGL3 basic vector (Promega), downstream of the luciferase gene. A clone (pGL3b KanR) was selected in which the kanamycin gene was inserted in the counterclockwise direction (not shown). The following primers were used to allow amplification of the luciferase/kanamycin cassette from this plasmid and its targeting for integration through 50 bp homology tails into the second exon of the ␤-globin gene: LuGnF 5Ј ctg act ctc tct gcc tat tgg tct att ttc cca ccc tta gGC TGC TGG TG GAA GAC GCC AAA AAC ATA AAG A 3Ј LuGmF 5Ј ctg act ctc tct gcc tat tag tct att ttc cca ccc tta gGC TGC TGG TG GAA GAC GCC AAA AAC ATA AAG A 3Ј LuGR 5Ј aag ggg aaa gaa aac atc aag ggt ccc ata gac tca cCC TGA AGT TCT CA caa gaa atc aca gcc gaa gcc 3Ј LuG1 5Ј aga cag gtt taa gga gac ca 3Ј LuG2 5Ј gtt tcc cat tct aaa ctg ta 3Ј The underlined sequences in primers LuGnF and LuGmF are from the 5Ј-end and in primer LuGR from the 3Ј-end of exon II of the ␤-globin gene (exon sequences are in capital letters). LuGnF and LuGmF contain at their 3Ј-ends the first 22 nucleotides of the luciferase sequence from pGL3b KanR, immediately downstream of the ATG initiation signal and differ from each other only at the position of the IVS I-110 mutation (bold). LuGR contains at its 3Ј-end a sequence derived upstream of the promoter region of the kanamycin resistance gene. Primers LuG1 and LuG2 are derived from IVS I and IVS II respectively and are used for PCR screening of recombinant clones. A product of 440 bp is expected in the absence of integration, while a 3321 bp product is expected after integration. (a) PCR analysis of five independent

colonies; C, parent EBAC/148␤ clone. (b) Sequence analysis of two recombinant clones obtained after electroporating a PCR product containing the luciferase/kanamycin cassette downstream of the IVS I-110 G → A mutation into DH10B (pGETrec, EBAC/148␤) cells. The 5Ј-end of the fusion in two of these clones was sequenced with primer LuG1. Both clones show the fusion of the luciferase gene from amino acid number 2 onwards to the last three amino acids of exon II of the ␤-globin gene. Clone 1 also contains the IVS I-110 G → A mutation present in primer LuGmR, while in clone 2 this seems to have been corrected back to the normal sequence.
PCRkan140 into the correct target site, with no evidence of rearrangements, as confirmed by PCR with primers KA and KB and by DNA sequencing of both regions of homology flanking the kanamycin gene (data not shown).
As there have been no previous reports using a system such as this with human BAC/PAC genomic clones, we attempted to modify the 200 kb ␤-globin clone EBAC/148␤ using PCRkan140 directly in the DH10B strain of E. coli. Electroporation of PCRkan140 into DH10B(pGETrec, EBAC/148␤) cells, induced with larabinose for 40 min before harvesting, yielded more than 1000 Cm r Km r recombinants per electroporation (Table 1, experiments 3 and 4) .
Twenty independent Cm r Km r clones gave the expected PCR product with primers KA and KB ( Figure  4) . The parent EBAC/148␤ clone generated the expected fragment of 393 bp. None of the recombinant clones generated this fragment, which would have been detected if integration of PCRkan140 had taken place elsewhere in EBAC/148␤ or in the host bacterial chromosome.
DNA was isolated from four of the primary Cm r Km r clones and re-electroporated into DH10B cells to purify the BAC away from the pGETrec plasmid. DNA from two independent secondary clones of each primary clone was analysed by pulsed field gel electrophoresis after digestion with NotI or XhoI ( Figure 5 ). NotI digestion (Figure 5a) showed that all eight secondary clones released the expected 185 kb ␤-globin insert without gross rearrangements. There was also a slight but obvious increase in the size of the NotI-digested vector band from all eight clones compared with the NotI-digested vector band of the parent clone EBAC/148␤, due to the change in size of the vector band after integration of PCRkan140 into its target site. The same eight clones were analysed after restriction digestion with XhoI (Figure 5b ). All showed the same restriction fragments as the control parent EBAC/148␤ clone, apart from the absence of a fragment of about 70 kb that is only observed in the parent clone. In the eight secondary clones, the 70 kb fragment was cut into two fragments of about 30 and 40 kb. The 40 kb fragment co-migrated with another fragment of about 40 kb in length that is present in the parent EBAC/148␤ clone, giving a significantly more intense band at this position for the Cm r Km r clones than the 40 kb band generated by the parent EBAC/148␤ clone. Since there is no XhoI site on the backbone of the parent vector, the 70 kb fragment must be derived from the backbone of the vector and adjoining globin sequences. After integration of PCRkan140 into the vector backbone by homologous recombination, the 70 kb fragment is cut into two smaller fragments at the single XhoI site, which is present in the kanamycin gene.
These results confirm that integration of PCRkan140 through homologous recombination had taken place correctly into the target site on the backbone of the vector in all four primary Cm r Km r clones. None of the clones displayed instability through this procedure, indicating that transient induction of homologous recombination in DH10B cells with the pGETrec plasmid minimises the risk of unwanted rearrangements in BAC clones at least up to 200 kb in size. Sequencing across the homology regions flanking the kanamycin gene in both EBAC/148␤::kan140 and pEBAC140::kan50 clones did not reveal any deviations from the expected sequence (data not shown).
PCR products incorporating homologous regions as short as 50 bp have been shown to recombine with good efficiency in JC8679 or JC9604 E. coli strains. 14 We tested this approach in our system by electroporating PCRkan50 into DH10B(pGETrec, EBAC/148␤) cells. More than 100 Cm r Km r colonies were obtained from each electroporation (Table 1 , experiments 5 and 6). Direct PCR screening of 20 independent cultures from these Cm r Km r colonies, using primers 140KF and 140KR, generated the correct 1450 bp product (data not shown). Although the frequency of recombinants was reduced about 10-fold using 50-mer targeting sites compared with 140-mer targeting sites, the accuracy of integration through homologous recombination was maintained.
We used a similar approach to introduce the IVS I-110 splicing mutation in the ␤-globin gene. This mutation is found at high frequency in many Mediterranean populations. 18 It creates a 3Ј acceptor splicing site mutation that is used preferentially over the normal site. The resulting mRNA carries the last 19 residues of intron I and its translation is prematurely terminated at the start of exon II. The apparent competition seen between normal and aberrant splicing pathways induced by this mutation indicates that it may be possible to modify the splicing specificity so as to increase the levels of normal ␤-globin chain production in such a way as to confer transfusion independence to patients carrying this mutation. We therefore wanted to use our technology to fuse the luciferase gene in frame to the ␤-globin gene just downstream of the IVS I-110 splicing mutation to construct a convenient cellular assay system for agents that could modify splicing specificity. DH10B(pGETrec, EBAC/148␤) electrocompetent cells, induced for 35 min with l-arabinose, were electroporated with the PCR product obtained from plasmid pGL3b KanR with primers LuGnF and LuGR (see legend to Figure 6 ). Recombinants were confirmed by PCR with primers LuG1 and LuG2. All recombinant clones examined by PCR appeared to contain the expected PCR product (Figure 6a) . A similar approach was used to introduce the luciferase/kanamycin cassette with the upstream IVS I-110 G → A mutation in the upstream primer, LuGmF, and two recombinant clones were sequenced with primer LuG1 (Figure 6b ). Although both clones showed the expected fusion of the luciferase and globin genes, only one of the clones was found to carry the IVS I-110 mutation. This is not unexpected, since repair of the mispaired bases at IVS I-110 between the incoming PCR product and the recipient molecule could result either in conversion to the mutant or reversion to the wild-type form. Work is in progress to characterise further this system as a potential high throughput screening system for agents that could modify splicing specificity.
In this work, we have modified the pBAD24-trecET plasmid (YZ and AFS, unpublished) by the introduction of the gam gene of bacteriophage so as to allow coordinated expression of the recE, recT and gam genes after induction with l-arabinose. The new plasmid, pGETrec, can co-exist stably with the BACs/PACs in E. coli DH10B cells. Using pGETrec, we demonstrate homologous recombination at high efficiency between linear PCR fragments and target sequences carrying either the 17 kb BAC vector pEBAC140, or a 200 kb pEBAC140-derived clone containing the intact human ␤-globin locus, EBAC/148␤. The procedure is outlined in Figure 7 .
The modification to ET cloning described here allows the introduction of any desirable modifications at any specific position in BACs and PACs in DH10B cells without rearrangements, and thus eliminates the need to transfer BACs/PACs to recombination proficient E. coli strains or to create special shuttling vectors. We presume that the tight regulation and fast kinetics of induction by l-arabinose 19 shown by the P BAD promoter in the pBAD series of vectors explain the lack of unwanted rearrangements observed in our system.
